AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11297574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11297574 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I treatment
Number of subjects: 16
Study 9043536 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg atropine sulfate added to the first nebulizer and saline in the second and third treatments
Number of subjects: 126
Study 9043536 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg atropine to the first and third treatments (with saline in the second)
Number of subjects: 126
Study 9043536 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo during all 3 treatments
Number of subjects: 126
Study 8196726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (4 mg per kilogram of body weight per day)
Number of subjects: 20
Study 8196726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8196726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (subsequent treatment for placebo non-responders)
Number of subjects: 20
Study 3286242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek (15 g) soaked in water
Number of subjects: 0
Study 29766285 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 795
Study 27208499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg)
Number of subjects: 90
Study 27208499 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)
Number of subjects: 90
Study 27208499 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.8 mg/kg)
Number of subjects: 90
Study 25106453 — intervention group
Group type: EXPERIMENTAL
Intervention: DA with values clarification exercise (VCE+)
Number of subjects: 135
Study 25106453 — intervention group
Group type: COMPARATOR
Intervention: DA with information only (VCE-)
Number of subjects: 135
Study 25106453 — intervention group
Group type: EXPERIMENTAL
Intervention: DA with information plus VCE without referral (VCE+)
Number of subjects: 135
Study 25106453 — intervention group
Group type: EXPERIMENTAL
Intervention: DA with information plus VCE with specific referral (VCE++)
Number of subjects: 135
Study 24206741 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with levofloxacin, amoxicillin, and a PPI for 10 days
Number of subjects: 81
Study 24206741 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with clarithromycin for 10 days
Number of subjects: 81
Study 21382863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation started within 24 hours post surgery
Number of subjects: 306
Study 18513531 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg PO twice daily for a total of 14 doses (3 preoperative)
Number of subjects: 102
Study 18513531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18513531 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 102
Study 16579728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh grapefruit
Number of subjects: 91
Study 16579728 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 91
Study 16579728 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit capsules
Number of subjects: 91
Study 16579728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 16579728 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit (all forms)
Number of subjects: 91
Study 12803788 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative amoxycillin
Number of subjects: 95
Study 12803788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 10926979 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 40
Study 10926979 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2%
Number of subjects: 40
Study 9208491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate (HPC)
Number of subjects: 0
Study 9208491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 0
Study 9208491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 0
Study 9208491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drugs (HPC + TMX, HPC + AG, TMX + AG)
Number of subjects: 0
Study 1443204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise for 30 minutes
Number of subjects: 22
Study 1443204 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control period
Number of subjects: 22
Study 1443204 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heating to vasodilate forearm skin
Number of subjects: 22
Study 7016089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fluoride treatment (gel + rinse)
Number of subjects: 0
Study 7016089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel treatment
Number of subjects: 0
Study 7016089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse treatment
Number of subjects: 0
Study 30714486 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy (ST)
Number of subjects: 35
Study 30714486 — intervention group
Group type: COMPARATOR
Intervention: Sham Treatment
Number of subjects: 35
Study 31099712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 80
Study 31099712 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus Metronidazole
Number of subjects: 80
Study 28724185 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus selenium (MI-Se) supplementation
Number of subjects: 168
Study 28724185 — intervention group
Group type: COMPARATOR
Intervention: Selenium alone
Number of subjects: 168
Study 26270587 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream applied to the forearm
Number of subjects: 12
Study 26270587 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 12
Study 24103057 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (50%)
Number of subjects: 12058
Study 24103057 — intervention group
Group type: COMPARATOR
Intervention: Control group (50%)
Number of subjects: 12058
Study 24103057 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol tests
Number of subjects: 12058
Study 24103057 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol
Number of subjects: 12058
Study 24103057 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 12058
Study 20672903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration of hydrosalpingeal fluid prior to IVF-ET
Number of subjects: 110
Study 20672903 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET without any prior intervention
Number of subjects: 110
Study 19169319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine-bupivicaine
Number of subjects: 136
Study 19169319 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine-bupivicaine
Number of subjects: 136
Study 16450373 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent, shed antigen, melanoma vaccine
Number of subjects: 117
Study 16450373 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 117
Study 16873344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate 30 mL p.o. and saline 2 mL i.v.
Number of subjects: 123
Study 16873344 — intervention group
Group type: COMPARATOR
Intervention: Water 30 mL p.o. and famotidine 20 mg i.v.
Number of subjects: 123
Study 12517843 — intervention group
Group type: EXPERIMENTAL
Intervention: NucliSens HIV-1 QT assay
Number of subjects: 101
Study 12517843 — intervention group
Group type: COMPARATOR
Intervention: Standard AMPLICOR test
Number of subjects: 101
Study 12517843 — intervention group
Group type: COMPARATOR
Intervention: NASBA assay
Number of subjects: 101
Study 10193813 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA treatment (3 mg/kg) after pretreatment with CAND (8 mg)
Number of subjects: 15
Study 10193813 — intervention group
Group type: COMPARATOR
Intervention: L‐NMMA treatment (3 mg/kg) after placebo
Number of subjects: 15
Study 10193813 — intervention group
Group type: EXPERIMENTAL
Intervention: CAND pretreatment
Number of subjects: 15
Study 10193813 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA treatment (3 mg/kg)
Number of subjects: 15
Study 8787253 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppositories
Number of subjects: 30
Study 8787253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Anusol)
Number of subjects: 30
Study 2194387 — intervention group
Group type: EXPERIMENTAL
Intervention: Single general practitioner visit backed up by a practice nurse
Number of subjects: 100
Study 7053160 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana inhalation
Number of subjects: 18
Study 29240962 — intervention group
Group type: EXPERIMENTAL
Intervention: AXXESS dedicated self‐expanding biolimus A9‐eluting bifurcation stent
Number of subjects: 123
Study 28350654 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tisseel) (n = 23)
Number of subjects: 96
Study 28350654 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (n = 26)
Number of subjects: 96
Study 28350654 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) (n = 27)
Number of subjects: 96
Study 28350654 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-site quilting sutures (n = 20)
Number of subjects: 96
Study 25246239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg), Vitamin E (400 mg), Zinc gluconate (25 mg), Selenomethionine (200 μg)
Number of subjects: 53
Study 25246239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25246239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin E, Zinc, and Selenium supplementation
Number of subjects: 53
Study 24001635 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (six 90-minute sessions)
Number of subjects: 54
Study 20963843 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm testing for antibiotic selection
Number of subjects: 39
Study 20963843 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic treatment
Number of subjects: 39
Study 18534087 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 150 mg p.o. twice daily
Number of subjects: 17
Study 18534087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16905684 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 284
Study 16905684 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 284
Study 16905684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 12885990 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygosity at position 27 of the β2 adrenergic receptor (ADRB2) polymorphism
Number of subjects: 587
Study 12885990 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism at position 16 of the β2 adrenergic receptor (ADRB2)
Number of subjects: 587
Study 11789186 — intervention group
Group type: EXPERIMENTAL
Intervention: Chang'ai Kangfu decoction (CAKF)
Number of subjects: 48
Study 11789186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CAKF plus chemotherapy)
Number of subjects: 48
Study 11789186 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (5-FU and mitomycin C)
Number of subjects: 48
Study 8888416 — intervention group
Group type: EXPERIMENTAL
Intervention: KR after every trial
Number of subjects: 2
Study 8888416 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary KR
Number of subjects: 2
Study 1892680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide plus methylprednisolone (arm A)
Number of subjects: 163
Study 1892680 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide plus methylprednisolone plus lorazepam (arm B)
Number of subjects: 163
Study 1892680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (arm A and arm B)
Number of subjects: 163
Study 6643694 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg dyphylline
Number of subjects: 20
Study 6643694 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg dyphylline
Number of subjects: 20
Study 6643694 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg dyphylline
Number of subjects: 20
Study 6643694 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg anhydrous theophylline
Number of subjects: 20
Study 6643694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31848050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Number of subjects: 1038
Study 31848050 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1038
Study 29557821 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected exercise adherence strategies (logs, graphs, pedometers, phone follow-up, education, and a letter from CR staff) provided for 6 weeks post CR and continued based on patient selection for the last 6 weeks.
Number of subjects: 20
Study 29557821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study 28112023 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (induced hypertension)
Number of subjects: 118
Study 28112023 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline (intravascular volume load)
Number of subjects: 118
Study 28112023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (cerebral arteriolar vasodilation)
Number of subjects: 118
Study 28112023 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down tilt (HDT) 15° (cerebral blood flow diversion)
Number of subjects: 118
Study 28112023 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 118
Study 27455513 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended-release (ER)
Number of subjects: 429
Study 27455513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 25530294 — intervention group
Group type: EXPERIMENTAL
Intervention: Active educational intervention (21 physicians) consisting of 1 small group discussion, 1 outreach visit, and 3 reminders.
Number of subjects: 317
Study 25530294 — intervention group
Group type: COMPARATOR
Intervention: Passive educational intervention (20 physicians) consisting of delivery of printed guidelines.
Number of subjects: 317
Study 22618381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study 22618381 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 12
Study 19679019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand foam used to cleanse hands and stethoscope head simultaneously
Number of subjects: 92
Study 19679019 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 92
Study 17241248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix) administered at 0, 7, 21 to 30 days, and 12 months
Number of subjects: 100
Study 17241248 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine (Engerix-B) administered at 0, 1, 2, and 12 months
Number of subjects: 100
Study 17241248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix)
Number of subjects: 100
Study 17241248 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis A vaccine (Havrix)
Number of subjects: 100
Study 17241248 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine (Engerix-B)
Number of subjects: 100
Study 17241248 — intervention group
Group type: COMPARATOR
Intervention: Monovalent vaccines (Havrix and Engerix-B)
Number of subjects: 100
Study 15274701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous alprostadil (low doses) with saline solution intravenously
Number of subjects: 80
Study 15274701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alprostadil with local saline solution injections
Number of subjects: 80
Study 15274701 — intervention group
Group type: COMPARATOR
Intervention: Saline solution around the ulcers and intravenously (Control)
Number of subjects: 80
Study 11526545 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.05 mg
Number of subjects: 0
Study 11526545 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg
Number of subjects: 0
Study 11526545 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Number of subjects: 0
Study 11526545 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg
Number of subjects: 0
Study 11526545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9248873 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg twice a day, doubled after 3 weeks if needed)
Number of subjects: 41
Study 9248873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg q.a.m., doubled after 3 weeks if needed)
Number of subjects: 41
Study 9248873 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (as comedication)
Number of subjects: 41
Study 8499506 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulated head cover applied within 1 minute of arrival in the operating room
Number of subjects: 0
Study 8499506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insulated head cover)
Number of subjects: 0
Study 3323227 — intervention group
Group type: EXPERIMENTAL
Intervention: Written interpretation of Gram stain results
Number of subjects: 301
Study 3323227 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gram stain results reported without interpretation)
Number of subjects: 301
Study 31750703 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hr nicotine deprivation
Number of subjects: 120
Study 31750703 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived
Number of subjects: 120
Study 30558092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric ropivacaine (15.2 mg) with 5 μg sufentanil
Number of subjects: 100
Study 30558092 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic infusion of phenylephrine (50 μg/min)
Number of subjects: 100
Study 27433861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophic resistance training (RT) for 6 weeks, two 40-minute sessions weekly, three sets of 12 repetitions at 67% to 85% one-repetition maximum for 10 whole-body exercises.
Number of subjects: 37
Study 25293375 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥8
Number of subjects: 447
Study 25293375 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥8 (women)
Number of subjects: 447
Study 25293375 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS cutoff point ≥7 (men)
Number of subjects: 447
Study 22990352 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg/day)
Number of subjects: 9711
Study 22990352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9711
Study 22990352 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on therapy (further diuretic and other drugs)
Number of subjects: 9711
Study 22990352 — intervention group
Group type: COMPARATOR
Intervention: No-add-on therapy
Number of subjects: 9711
Study 21109670 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation intervention (students wrote about their most important values, twice at the beginning of the course)
Number of subjects: 399
Study 21109670 — intervention group
Group type: COMPARATOR
Intervention: Control group (students did not write about their values)
Number of subjects: 399
Study 19075206 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 252
Study 19075206 — intervention group
Group type: COMPARATOR
Intervention: Outpatient, hospital-based rehabilitation
Number of subjects: 252
Study 16099421 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 120
Study 16099421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-focussing
Number of subjects: 120
Study 16099421 — intervention group
Group type: COMPARATOR
Intervention: Control (no imagery)
Number of subjects: 120
Study 12548129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g every 8 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Number of subjects: 219
Study 12548129 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir (800 mg every 6 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Number of subjects: 219
Study 12548129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 219
Study 12548129 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 219
Study 10077376 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol group (ES, n = 30)
Number of subjects: 60
Study 10077376 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia group (BC, n = 30)
Number of subjects: 60
Study 10077376 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol group (ES)
Number of subjects: 60
Study 10077376 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia group (BC)
Number of subjects: 60
Study 7720762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 42
Study 7720762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2242108 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with casein-to-whey ratio of 82:18
Number of subjects: 40
Study 2242108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-casein formula (82:18)
Number of subjects: 40
Study 2242108 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed groups (decreasing casein concentration)
Number of subjects: 40
Study 2242108 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 40
Study 7261627 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment group
Number of subjects: 0
Study 7261627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrothyroxine
Number of subjects: 0
Study 7261627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30817251 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSTVAC (Arm V)
Number of subjects: 1297